Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 716-726

  Hsiang, J C ^a   Wong, G L H ^a,b   Chan, H L Y ^a,b   Chan, A W H ^a   Chim, A M L ^a,b   Wong, V W S ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG;

ADULT; AGE; ARTICLE; CHINESE; CLEARANCE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS B; HIGH RISK PATIENT; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCLEARANCE; VIRUS LOAD;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84906246654     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12874     Document Type: Article

References (37)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Chan HL, Sung JJ,. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-61.
3. Wong GL, Wong VW, Choi PC, et al,. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-7.
4. Huang YW, Wang TC, Lin SC, et al,. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis 2013; 57: 1695-702.
5. Chen CL, Yang HI, Yang WS, et al,. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-21.
6. Jan CF, Chen CJ, Chiu YH, et al,. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes 2006; 30: 794-9.
7. Chao LT, Wu CF, Sung FY, et al,. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011; 32: 876-81.
8. Paradis V, Perlemuter G, Bonvoust F, et al,. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34 (4 Pt 1): 738-44.
9. Starley BQ, Calcagno CJ, Harrison SA,. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
10. Chan HL, Wong GL, Wong VW,. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489-99.
11. Liu CJ, Chen PJ, Lai MY, et al,. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006; 26: 949-55.
12. Hsu YS, Chien RN, Yeh CT, et al,. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
13. Chen YC, Chu CM, Liaw YF,. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
14. Ates F, Yalniz M, Alan S,. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol 2011; 17: 4517-22.
15. Cindoruk M, Karakan T, Unal S,. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007; 41: 513-7.
16. Chung WG, Kim HJ, Choe YG, et al,. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naive patients with chronic hepatitis B infection. Clin Mol Hepatol 2012; 18: 195-202.
17. Manolakopoulos S, Bethanis S, Liapi C, et al,. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol 2007; 7: 17.
18. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ,. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS ONE 2012; 7: e34198.
19. Chan HL, Wong GL, Choi PC, et al,. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
20. Boursier J, Zarski JP, de Ledinghen V, et al,. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182-91.
21. Kleiner DE, Brunt EM,. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
22. Consultation WHOE,. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
23. Alberti KG, Eckel RH, Grundy SM, et al,. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
24. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
25. Nestel P, Lyu R, Low LP, et al,. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr 2007; 16: 362-7.
26. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S,. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 2013; 62: 697-703.
27. Lai MS, Hsieh MS, Chiu YH, Chen TH,. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-302.
28. Wong GL, Chan HL, Yu Z, et al,. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B-a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014; 39: 883-93.
29. Despres JP,. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-9.
30. Chu CM, Lin DY, Liaw YF,. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci 2013; 58: 275-81.
31. Chiang CH, Lai JS, Hung SH, Lee LT, Sheu JC, Huang KC,. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring) 2013; 21: 291-6.
32. Wong VW, Wong GL, Yu J, et al,. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010; 105: 132-8.
33. Liu CJ, Chen PJ, Lai MY, et al,. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int 2009; 3: 364-70.
34. Tilg H, Moschen AR,. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
35. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI,. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
36. Fabrizi F, Dixit V, Martin P, Messa P,. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011; 33: 815-21.
37. Bandaru P, Rajkumar H, Nappanveettil G,. Altered or impaired immune response to hepatitis B vaccine in WNIN/GR-Ob rat: an obese rat model with impaired glucose tolerance. ISRN Endocrinol 2011; 2011: 980105.